Next Article in Journal
Improving Co-Amorphous Drug Formulations by the Addition of the Highly Water Soluble Amino Acid, Proline
Previous Article in Journal
Release of Tenofovir from Carrageenan-Based Vaginal Suppositories
Previous Article in Special Issue
Preliminary Studies on Validation of Calu-3 Cell Line as a Model for Screening Respiratory Mucosa Irritation and Toxicity
Pharmaceutics 2014, 6(3), 378-415; doi:10.3390/pharmaceutics6030378
Review

Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives

,
 and *
Received: 18 February 2014; in revised form: 20 June 2014 / Accepted: 24 June 2014 / Published: 10 July 2014
(This article belongs to the Special Issue Respiratory and Nasal Drug Delivery)
View Full-Text   |   Download PDF [1638 KB, updated 23 July 2014; original version uploaded 10 July 2014]   |   Browse Figures
Abstract: Intranasal delivery of DNA vaccines has become a popular research area recently. It offers some distinguished advantages over parenteral and other routes of vaccine administration. Nasal mucosa as site of vaccine administration can stimulate respiratory mucosal immunity by interacting with the nasopharyngeal-associated lymphoid tissues (NALT). Different kinds of DNA vaccines are investigated to provide protection against respiratory infectious diseases including tuberculosis, coronavirus, influenza and respiratory syncytial virus (RSV) etc. DNA vaccines have several attractive development potential, such as producing cross-protection towards different virus subtypes, enabling the possibility of mass manufacture in a relatively short time and a better safety profile. The biggest obstacle to DNA vaccines is low immunogenicity. One of the approaches to enhance the efficacy of DNA vaccine is to improve DNA delivery efficiency. This review provides insight on the development of intranasal DNA vaccine for respiratory infections, with special attention paid to the strategies to improve the delivery of DNA vaccines using non-viral delivery agents.
Keywords: DNA vaccine; intranasal delivery; infectious diseases; respiratory pathogens; adjuvants; mucosal DNA vaccine; intranasal delivery; infectious diseases; respiratory pathogens; adjuvants; mucosal
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Xu, Y.; Yuen, P.-W.; Lam, J.K.-W. Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. Pharmaceutics 2014, 6, 378-415.

AMA Style

Xu Y, Yuen P-W, Lam JK-W. Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. Pharmaceutics. 2014; 6(3):378-415.

Chicago/Turabian Style

Xu, Yingying; Yuen, Pak-Wai; Lam, Jenny K.-W. 2014. "Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives." Pharmaceutics 6, no. 3: 378-415.


Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert